Tweet by Dr. John Cush

JAK inhibitor labeling in Canada updated to include risks of MACE, fatal VTE and cancer for tofacitinib (Xeljanz) (also applied to Cibinqo, Inrebic, Jakavi, Olumiant, Rinvoq Xeljanz)